News & Videos - ABCAM ORD 0.2P

Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its final results for the 18-month period ended 31 December 2021 (the ‘period’). The...

CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six- and 12-month periods ended 30 June 2021 (the ‘period’). The Group’s accounting reference date has changed from 30 June to 31 December 1 , therefore these interim financial statements report on both a six- and 12-month period. SUMMARY...

CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”). Transaction highlights BioVision is a fast-growing innovator and...

Building on existing three-year collaboration Focusing on co-development of companion and in vitro diagnostic kits to support demand in China CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced...

CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Research & Development received the CiteAb award for ‘ Significant Individual Impact’ and the Company was recognized as ‘ Antibody Supplier Succeeding in Cardiovascular Research’ . On receiving her award, Dr Alejandra Solache, SVP of R&D, Abcam, said: “Thank you very much to the team at...

CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“ Abcam ”, the “ Group ” or the “ Company ”), a global leader in the supply of life science research tools, today announces its interim results for the six month period ended 31 December 2020 (“ H1 2021 ”). SUMMARY PERFORMANCE Reported Adjusted 1 H1 2021 £m H1 2020 £m H1 2021 £m H1 2020 £m Revenue 147.5 138.2 147.5 138.2 Gross profit margin, % 70.9% 69.7% 70.9% 69.7% Operating...

Scaling up R&D, manufacturing and commercial capabilities in Shanghai and Hangzhou Investing in state-of-the-art facilities and equipment to support research, diagnostic and clinical applications CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer service,...

CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“ Abcam ” or the “ Company ”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, 2021. Following the announcement, the Company will host a live teleconference and webcast at 2:00 p.m. GMT (9:00 a.m. EST) that same day (details below). To access the...

CAMBRIDGE, United Kingdom, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; LSE: ABC) today announced that Alan Hirzel, Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8.00 EST / 13.00 GMT. A live webcast of the presentation can be accessed via the IR Calendar page of Abcam’s Investor Relations website at https://www.abcamplc.com/reports-presentations . Contact: James Staveley, VP, Investor Relations...

CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“ Abcam ”), a global leader in the supply of life science research tools, is delighted to announce the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect. Both Bessie and Mark bring extensive and complementary executive and non-executive experience to the Board of Abcam. Based in China, Bessie Lee is the Chief Executive Officer of Withinlink, a China-based...

CAMBRIDGE, United Kingdom, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“ Abcam ”), a global leader in the supply of life science research tools, announces the following unaudited trading update ahead of reporting its results on 8 March 2021 for the six months ended 31 December 2020. Overall, we expect to report total first half revenue of £147.5 million (H1 2020: £138.2 million), representing growth of 8.3% on a constant currency basis and 6.7% on a reported...

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 September 2020 of its final results for the year ended 30 June 2020, the Abcam plc Annual Report and Accounts 2020 (the “Annual Report”) have been published today and are available on the Abcam plc website at www.abcamplc.com . A copy of the Annual Report has been submitted to the National...

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consultation with shareholders on the Group’s overall LTIP structure and performance framework, including proposed changes for this year’s awards, it has determined to retain the existing LTIP metrics and targets contained in Abcam’s current Remuneration Policy, as approved by shareholders in 2018....

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (" Abcam "), a global leader in the supply of life science research tools, announces today the closing of its offering of an aggregate of...

LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (“ Abcam ”), a global leader in the supply of life science research tools, announces today the pricing of its offering of 8,945,218 American Depositary Shares (“ ADSs ”), representing an aggregate of 8,945,218 ordinary shares, at a price of $17.50 per ADS, for aggregate proceeds of approximately $156.5 million, before deducting underwriting discounts and commissions. Each ADS offered represents one ordinary share of Abcam....

Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability PR Newswire CAMBRIDGE, England, Jan. 6, 2020 - Includes leading protein conjugation technologies and industry brands Lightning-Link ® and CaptSure™ - Opportunity to combine Expedeon and Abcam's technologies to create new products to support research and diagnostic development CAMBRIDGE, England , Jan. 6, 2020 /PRNewswire/ -- Abcam plc, a global innovator in life...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: OCTOPUS INVESTMENTS LIMITED (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: HARGREAVE HALE LIMITED (for Discretionary Clients) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: OCTOPUS INVESTMENTS LIMITED (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: HARGREAVE HALE LIMITED (for Discretionary Clients) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....